In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...
Naismith et al. state that they preferentially recruited patients with severe optic neuritis (with ≤20/200 vision) and poor recovery (to <20/40 vision).This bias in selecting study participants ...
The trial met safety and efficacy endpoints. OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback